# Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution

> **NCT07226726** · PHASE1 · RECRUITING · sponsor: **The Foundation for Orthopaedics and Regenerative Medicine** · enrollment: 20 (estimated)

## Conditions studied

- Congenital Myasthenic Syndrome

## Interventions

- **BIOLOGICAL:** AlloEx exosomes

## Key facts

- **NCT ID:** NCT07226726
- **Lead sponsor:** The Foundation for Orthopaedics and Regenerative Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07226726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07226726, "Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07226726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*